Grant: Master's Award: Canada Graduate Scholarships
University of Saskatchewan
$17,500.00
Developing protein-based inhibitors of protein phosphatase 2A subunits for validation as cancer targets
EF 2015-16
Résumé
Current therapeutic approaches available for cancer treatment largely involve systemic drug-radiotherapy combinations. The non-specific nature of these therapeutics, which target cellular pathways common to both normal and tumour cells, lead to devastating side effects and damage to normal tissue. By targeting signalling pathways that are specific or up regulated in cancer cells, we can minimize the side effects. Here we propose to explore the potential of targeting protein phosphatase 2A (PP2A) for targeted therapy of cancer. Recent evidence suggests that drugs such as cantharidin and LB100 that inhibit PP2A function can cause lethality to cancer cells, while also overcoming drug and radiation resistance. However, there is no clear understanding of how these drugs affect cancer cells. PP2A is an incredibly complex enzyme with varied functions interacting in multiple signalling pathways. It is a multi-subunit complex assembled from a pool of these interchangeable subunits. More than 96 different versions of the protein exist in the cell with each of them capable of affecting different functions. It is our objective to determine which of these functions are essential for cancer cell viability. Since it is not possible to generate small molecule drugs that are specific for each of the PP2A variants, we plan to develop protein-based inhibitors. An advanced protein engineering technique, called phage-display, will be used to generate protein-based affinity reagents that specifically bind individual PP2A subunits and inhibit their activity. The generation of such inhibitors will allow for the identification of those subunits that act in relevant signalling pathways important for cancer cell proliferation and survival.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350085
Name
Templeton Shaina D
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing protein-based inhibitors of protein phosphatase 2A subunits for validation as cancer targets
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Therapeutic Targets; Phage Display; Pp2a Regulatory Subunits; Protein Phosphatase 2a; Protein-Based Inhibitors; Tumourigenic Or Tumour Suppressive Properties
Abstract
Current therapeutic approaches available for cancer treatment largely involve systemic drug-radiotherapy combinations. The non-specific nature of these therapeutics, which target cellular pathways common to both normal and tumour cells, lead to devastating side effects and damage to normal tissue. By targeting signalling pathways that are specific or up regulated in cancer cells, we can minimize the side effects. Here we propose to explore the potential of targeting protein phosphatase 2A (PP2A) for targeted therapy of cancer. Recent evidence suggests that drugs such as cantharidin and LB100 that inhibit PP2A function can cause lethality to cancer cells, while also overcoming drug and radiation resistance. However, there is no clear understanding of how these drugs affect cancer cells. PP2A is an incredibly complex enzyme with varied functions interacting in multiple signalling pathways. It is a multi-subunit complex assembled from a pool of these interchangeable subunits. More than 96 different versions of the protein exist in the cell with each of them capable of affecting different functions. It is our objective to determine which of these functions are essential for cancer cell viability. Since it is not possible to generate small molecule drugs that are specific for each of the PP2A variants, we plan to develop protein-based inhibitors. An advanced protein engineering technique, called phage-display, will be used to generate protein-based affinity reagents that specifically bind individual PP2A subunits and inhibit their activity. The generation of such inhibitors will allow for the identification of those subunits that act in relevant signalling pathways important for cancer cell proliferation and survival.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Templeton, Shaina D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~